Take a proactive approach to opioid-induced constipation (OIC) to help increase the number of spontaneous bowel movements1
For adult patients with chronic pain and opioid-induced constipation (OIC)1
RELISTOR helps restore gut function1-6
Take a proactive approach to opioid-induced constipation (OIC) to help increase the number of spontaneous bowel movements1
Discover RELISTOR tablets
RELISTOR tablets provide patients with chronic non-cancer pain (CNCP) and OIC the convenience of once-daily oral therapy.1
Discover RELISTOR injection
RELISTOR injection is indicated for the treatment of OIC in patients with CNCP. RELISTOR injection is also indicated for the treatment of OIC in adults with advanced illness or pain caused by active cancer who require opioid dosage escalation for palliative care.1
REFERENCES: 1. RELISTOR [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals. 2. Rauck R, Slatkin NE, Stambler N, Harper JR, Israel RJ. Randomized, double-blind trial of oral methylnaltrexone for the treatment of opioid-induced constipation in patients with chronic noncancer pain. Pain Practice. 2017;17(6):820-828. 3. Streicher JM, Bilsky EJ. Peripherally acting μ-opioid receptor antagonists for the treatment of opioid-related side effects: mechanism of action and clinical implications. J Pharm Pract. 2018;31(6):658-669. 4. Bader S, Jaroslawski K, Blum HE, Becker G. Opioid-induced constipation in advanced illness: safety and efficacy of methylnaltrexone bromide. Clin Med Insights Oncol. 2011;5:201-211. 5. Yuan CS, Foss JF, Osinski J, Toledano A, Roizen MF, Moss J. The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time. Clin Pharmacol Ther. 1997;61(4):467-475. 6. Yuan CS, Wei G, Foss JF, O’Connor M, Karrison T, Osinski J. Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. J Pharmacol Exp Ther. 2002;300(1):118-123.